Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Receipt of IRB Approval to Initiate Hemopurifier™ Clinical Studies

SAN DIEGO - September 2, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas.

Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that would allow for the initiation of Hemopurifier® feasibility studies in the United States. As a result of the independent IRB approval, the Company is now permitted to initiate the IDE approved study. Enrollment of patients who meet the study inclusion/exclusion criteria is expected to begin in the coming weeks. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.

Breaking Tech News: Nxt-ID (OTCQB: NXTD) Patents Methods to Add Electronics to Make a Wallet Smart

SHELTON, CT - September 2, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD), a biometric authentication company focused on the growing mobile commerce market, announced today that it has submitted a patent application for methods to integrate intelligent systems into a wallet to form a smart wallet. This patent primarily discusses mechanical methods and approaches to add electronics to turn average wallets into smart wallets and follows an earlier patent submission by the Company for a method to replace traditional payment and identity management systems.

"This patent reinforces our intellectual property position in the mobile and wearable markets, especially in the area of smart wallets," states David Tunnell, CTO of NXT-ID. "This invention details how various electronics, such as touch screens, buttons, batteries and microphones with voice recognition can be added to materials, providing tight integration that enhances wallet functionality."

GenSpera (OTCQB:GNSZ) Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids

SAN ANTONIO - August 28, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids.

The recent article co-authored by Doan, et al. (see full reference below), reviews the evolution and development of GenSpera's prodrug technology platform that is designed to deliver the potent, cytotoxic activity of thapsigargin (from the plant Thapsia garganica) directly to tumors. These efforts led to the development of mipsagargin (G-202), which is now in Phase II clinical trials in liver cancer and brain cancer.

The article details the discovery and isolation of thapsigargin, the elucidation of its molecular structure, and determination of its biochemical and pharmacological activities.

Breaking Tech News: Nxt-ID (OTCQB: NXTD) CNBC Ad Schedule for Wocket(TM) Smart Wallet to Resume for September Targeting New York and Los Angeles Markets

SHELTON, CT - August 28, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD), a biometric authentication company focused on the growing m-commerce market, announces the 30 second spots on CNBC for its next generation smart wallet, Wocket™ will resume in September, starting with targeted New York financial markets.

The CNBC advertisements will air daily during prime-time morning and afternoon programs.

NXT-ID's CEO Gino Pereira said, "We are continuing our successful national ad campaign with a more targeted regional approach to markets that have a high propensity to embrace our smart wallet biometric payment technology. Focusing on a financial audience with a higher daily frequency of the 30 second spots will create more brand awareness as we commence our first shipments to consumers this fall. We will follow the New York and Los Angeles market ads with select cities across the U.S. as we continue to introduce the Wocket to consumers."